Asarina Pharma AB Ordinary Shares ASAP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 0.95
- Day Range
- SEK 0.92–0.95
- 52-Week Range
- SEK 0.60–1.63
- Bid/Ask
- SEK 0.88 / SEK 0.98
- Market Cap
- SEK 21.51 Mil
- Volume/Avg
- 22,785 / 26,183
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.asarinapharma.com
Valuation
|
Metric
|
ASAP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.96 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ASAP
|
|---|---|
Quick Ratio | 2.77 |
Current Ratio | 2.77 |
Interest Coverage | −276.91 |
Quick Ratio
ASAP
Profitability
|
Metric
|
ASAP
|
|---|---|
Return on Assets (Normalized) | −95.09% |
Return on Equity (Normalized) | −111.04% |
Return on Invested Capital (Normalized) | −110.64% |
Return on Assets
ASAP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lgdcnjkv | Nldk | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fmnvymdp | Krzlh | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vmdjkfzk | Fkpyhbp | $99.5 Bil | |
MRNA
| Moderna Inc | Gvqfxnh | Wps | $38.8 Bil | |
ARGX
| argenx SE ADR | Stvcrtrfx | Lkgsw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Zbnspqft | Bxbb | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zvjthhwl | Qjszf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Txyclkwd | Rhnkmqv | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vvsnrmwm | Svgml | $12.5 Bil | |
INCY
| Incyte Corp | Cpvylpfk | Mskwgx | $11.6 Bil |